Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-25-186417
Filing Date
2025-08-22
Accepted
2025-08-22 16:05:32
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 d891898d424b5.htm 424B5 6736
2 GRAPHIC g891898g0822191123725.jpg GRAPHIC 4856
  Complete submission text file 0001193125-25-186417.txt   14728
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-268143 | Film No.: 251246277
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)